title: Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.
abstract: BACKGROUND
  Although recent studies suggest high accuracy of breast magnetic resonance imaging (MRI) in predicting residual tumor extent after neo-adjuvant systemic treatment (NST), its use is still controversial. In this study, we aimed to identify predictive factors of MRI accuracy after NST to determine a subgroup of patients in whom the use of MRI provides best additional benefit.
  
  
  METHODS
  Clinicopathologic and molecular profiles of breast cancer patients were investigated and their relationships with MRI accuracy were analyzed.
  
  
  RESULTS
  From January 2006 to February 2008, 195 patients received NST and preoperative MRI. In overall, MRI predicted residual tumor extent with higher accuracy than ultrasonography. Triple-negative (TN) tumors showed highest correlation between MRI-measured and pathologic tumor size (r = 0.781) when compared with other subtypes. Multivariate analysis showed age and HER2 expression status as independent factors predicting MRI accuracy. When patients were classified based on their age and HER2 status, relatively older patients (>45) with HER2-negative tumors showed highest MRI accuracy. This finding was further validated using an independent cohort of 63 consecutive patients.
  
  
  CONCLUSIONS
  Age and HER2 status independently affected MRI accuracy after NST. This observation may guide more tailored approach in using MRI in breast cancer patients undergoing NST.
authors.affiliation: Department of Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Chongno-Gu, Seoul, Korea.
authors.forename: H-G
authors.initials: HG
authors.lastname: Moon
authors.forename: W
authors.initials: W
authors.lastname: Han
authors.forename: J W
authors.initials: JW
authors.lastname: Lee
authors.forename: E
authors.initials: E
authors.lastname: Ko
authors.forename: E-K
authors.initials: EK
authors.lastname: Kim
authors.forename: J-H
authors.initials: JH
authors.lastname: Yu
authors.forename: S Y
authors.initials: SY
authors.lastname: Kang
authors.forename: W K
authors.initials: WK
authors.lastname: Moon
authors.forename: N
authors.initials: N
authors.lastname: Cho
authors.forename: I-A
authors.initials: IA
authors.lastname: Park
authors.forename: D-Y
authors.initials: DY
authors.lastname: Oh
authors.forename: S-W
authors.initials: SW
authors.lastname: Han
authors.forename: S-A
authors.initials: SA
authors.lastname: Im
authors.forename: D-Y
authors.initials: DY
authors.lastname: Noh
mesh_terms: D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D018734:Genes, erbB-2; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000592:standards*; D008875:Middle Aged; D015999:Multivariate Analysis
chemical_list: D000970:Antineoplastic Agents